首页 > 最新文献

Oncologia i radiologia Kazakhstana最新文献

英文 中文
EPIDEMIOLOGICAL SITUATION OF SKIN CANCER AND MELANOMIA IN THE REPUBLIC OF KAZAKHSTAN IN 2012-2022 2012-2022 年哈萨克斯坦共和国皮肤癌和黑色素瘤的流行病学状况
Pub Date : 2024-04-10 DOI: 10.52532/2663-4864-2024-1-71-12-21
D. Tuleuova, G. Serikbayev, А. Kurmanalyev, Z. Pyssanova, А. Yelekbayev
Relevance: Skin cancer, including melanoma, is a major health problem and one of the most common cancers in the world. The study aimed to obtain a complete epidemiological picture of skin cancer and melanoma in the Republic of Kazakhstan for 11 years, including analysis of data for 2022, considering various parameters such as age, sex, ethnicity, region, and tumor type. Methods: The study used data from patients registered in the national cancer registry of the Republic of Kazakhstan from 2012 to 2022, diagnosed with skin carcinoma and skin melanoma (ICD-10 code: C44-C43). The number of skin carcinomas and melanoma cases is presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality rates were calculated using the world standard (World). Results: At the end of 2022, 19,714 and 2,689 patients were diagnosed with “Skin Cancer” or “Skin Melanoma” in the Republic of Kazakhstan, respectively. From 2012 to 2022, the incidence of skin cancer increased by 24% and melanoma by 15%. In 2022, the incidence of skin cancer and melanoma was higher among women by 24% and 26%, respectively. Mortality from skin cancer is in 23rd place, from melanoma in 21st place. Mortality rates from skin cancer and melanoma were 0.5 and 0.7 per 100 thousand population, respectively. The peak incidence of skin cancer in 2022 was observed in the age group 65-74 years (36%), and mortality in the age groups 65-74 and 75-84 years (17% each). The peak incidence of skin melanoma in 2022 was observed in the age groups 55-64 years and 65-74 years (24% and 25%), and mortality in the groups 45-54 years and 35-44 years (14% and 10%). Conclusion: There has been a steady increase in the incidence of skin cancer and melanoma, which indicates the seriousness of this problem in the country and underlines the need for further measures to prevent, diagnose and treat skin cancer and melanoma in the Republic of Kazakhstan. It should be remembered that many cases of skin cancer can be prevented with simple precautions.
相关性:包括黑色素瘤在内的皮肤癌是一个重大健康问题,也是世界上最常见的癌症之一。本研究旨在全面了解哈萨克斯坦共和国 11 年来皮肤癌和黑色素瘤的流行病学情况,包括分析 2022 年的数据,并考虑年龄、性别、种族、地区和肿瘤类型等各种参数。研究方法研究使用的数据来自哈萨克斯坦共和国国家癌症登记处2012年至2022年登记的确诊为皮肤癌和皮肤黑色素瘤(ICD-10代码:C44-C43)的患者。皮肤癌和黑色素瘤病例数以每十万人的绝对比率和粗比率表示。绝对标准化发病率和死亡率采用世界标准(World)计算。结果:截至2022年底,哈萨克斯坦共和国分别有19714名和2689名患者被诊断为 "皮肤癌 "或 "皮肤黑色素瘤"。从 2012 年到 2022 年,皮肤癌发病率增加了 24%,黑色素瘤发病率增加了 15%。2022 年,妇女的皮肤癌和黑色素瘤发病率分别增加了 24%和 26%。皮肤癌死亡率排名第 23 位,黑色素瘤死亡率排名第 21 位。皮肤癌和黑色素瘤的死亡率分别为每 10 万人 0.5 例和 0.7 例。2022 年,皮肤癌的发病高峰出现在 65-74 岁年龄组(36%),死亡率则出现在 65-74 岁和 75-84 岁年龄组(各占 17%)。2022 年,皮肤黑色素瘤的发病高峰出现在 55-64 岁和 65-74 岁年龄组(分别为 24% 和 25%),死亡率则出现在 45-54 岁和 35-44 岁年龄组(分别为 14% 和 10%)。结论皮肤癌和黑色素瘤的发病率持续上升,这表明我国这一问题的严重性,并强调哈萨克斯坦共和国需要采取进一步措施预防、诊断和治疗皮肤癌和黑色素瘤。应当记住,许多皮肤癌病例可以通过简单的预防措施加以预防。
{"title":"EPIDEMIOLOGICAL SITUATION OF SKIN CANCER AND MELANOMIA IN THE REPUBLIC OF KAZAKHSTAN IN 2012-2022","authors":"D. Tuleuova, G. Serikbayev, А. Kurmanalyev, Z. Pyssanova, А. Yelekbayev","doi":"10.52532/2663-4864-2024-1-71-12-21","DOIUrl":"https://doi.org/10.52532/2663-4864-2024-1-71-12-21","url":null,"abstract":"Relevance: Skin cancer, including melanoma, is a major health problem and one of the most common cancers in the world. \u0000The study aimed to obtain a complete epidemiological picture of skin cancer and melanoma in the Republic of Kazakhstan for 11 years, including analysis of data for 2022, considering various parameters such as age, sex, ethnicity, region, and tumor type. \u0000Methods: The study used data from patients registered in the national cancer registry of the Republic of Kazakhstan from 2012 to 2022, diagnosed with skin carcinoma and skin melanoma (ICD-10 code: C44-C43). The number of skin carcinomas and melanoma cases is presented as absolute and crude rates per 100,000 population. Absolute standardized morbidity and mortality rates were calculated using the world standard (World). \u0000Results: At the end of 2022, 19,714 and 2,689 patients were diagnosed with “Skin Cancer” or “Skin Melanoma” in the Republic of Kazakhstan, respectively. From 2012 to 2022, the incidence of skin cancer increased by 24% and melanoma by 15%. In 2022, the incidence of skin cancer and melanoma was higher among women by 24% and 26%, respectively. Mortality from skin cancer is in 23rd place, from melanoma in 21st place. Mortality rates from skin cancer and melanoma were 0.5 and 0.7 per 100 thousand population, respectively. The peak incidence of skin cancer in 2022 was observed in the age group 65-74 years (36%), and mortality in the age groups 65-74 and 75-84 years (17% each). The peak incidence of skin melanoma in 2022 was observed in the age groups 55-64 years and 65-74 years (24% and 25%), and mortality in the groups 45-54 years and 35-44 years (14% and 10%). \u0000Conclusion: There has been a steady increase in the incidence of skin cancer and melanoma, which indicates the seriousness of this problem in the country and underlines the need for further measures to prevent, diagnose and treat skin cancer and melanoma in the Republic of Kazakhstan. It should be remembered that many cases of skin cancer can be prevented with simple precautions.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140719534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA BREAKS AND REPAIR IN LYMPHOCYTES AS A DIAGNOSTIC MARKER IN PATIENTS WITH GASTRIC CANCER 淋巴细胞中的 DNA 断裂和修复作为胃癌患者的诊断指标
Pub Date : 2024-04-10 DOI: 10.52532/2663-4864-2024-1-71-35-39
A. Tulyayeva, E. Iztleuov, A. Koishybaev, P. Aitmagambet, N. Imanbayev, G. Zhurabekova, G. Batyrova, D. Zholmukhamedova, N. Kereeva, M. Aitmagambetova
Relevance: Colorectal cancer (CRC), arising from the right-sided or left-sided colon, is a separate clinical and pathological unit. The status of KRAS and its predictive value in CRC remain controversial. The study aimed to explore the effect of primary tumor localization on KRAS gene status in CRC. Methods: The study included 60 patients with colon and rectal cancer. The KRAS mutation test was performed on paraffin-coated tumor samples using PCR methods. Colon cancer was divided into right-sided colon cancer (RSCC) and left-sided colon cancer (LSCC). Results: KRAS mutation was found much more often in rectal cancer (RC) and sigmoid colon (SC) (p=0.413) than in tumors in other parts of the colon. A combined analysis of our data and previously published data showed that KRAS mutation was more common in PSTC, especially in the area of the hepatic bend of the colon than in LSTC (p=0.120). The association of the KRAS mutation with the patient’s age (p<0.012) and the duration of hospitalization (p<0.001) was established.> Conclusion: Our study revealed no significant difference in the KRAS status between colon cancer and rectal cancer. However, KRAS mutation was much more common in RSCC compared to LSCC. Patients with RSCC with mutated KRAS also had a worse prognosis and required longer hospitalization compared to wild-type KRAS. However, patients with LSCC did not demonstrate a similar effect.
相关性:结直肠癌(CRC)发生于右侧或左侧结肠,是一个独立的临床和病理单元。KRAS 在 CRC 中的地位及其预测价值仍存在争议。本研究旨在探讨原发肿瘤定位对 CRC 中 KRAS 基因状态的影响。研究方法研究纳入了 60 名结肠癌和直肠癌患者。采用 PCR 方法对石蜡包衣肿瘤样本进行 KRAS 基因突变检测。结肠癌分为右侧结肠癌(RSCC)和左侧结肠癌(LSCC)。结果显示与结肠其他部位的肿瘤相比,直肠癌(RC)和乙状结肠(SC)中发现 KRAS 突变的频率更高(P=0.413)。对我们的数据和以前发表的数据进行的综合分析表明,KRAS突变在PSTC中更为常见,尤其是在结肠肝弯区域(P=0.120)。KRAS突变与患者年龄的关系(P 结论:KRAS突变与患者年龄无关:我们的研究显示,结肠癌和直肠癌的 KRAS 状态无明显差异。然而,与直肠癌相比,KRAS 突变在 RSCC 中更为常见。与野生型 KRAS 相比,KRAS 突变的 RSCC 患者预后更差,住院时间更长。然而,LSCC 患者并没有表现出类似的影响。
{"title":"DNA BREAKS AND REPAIR IN LYMPHOCYTES AS A DIAGNOSTIC MARKER IN PATIENTS WITH GASTRIC CANCER","authors":"A. Tulyayeva, E. Iztleuov, A. Koishybaev, P. Aitmagambet, N. Imanbayev, G. Zhurabekova, G. Batyrova, D. Zholmukhamedova, N. Kereeva, M. Aitmagambetova","doi":"10.52532/2663-4864-2024-1-71-35-39","DOIUrl":"https://doi.org/10.52532/2663-4864-2024-1-71-35-39","url":null,"abstract":"Relevance: Colorectal cancer (CRC), arising from the right-sided or left-sided colon, is a separate clinical and pathological unit. The status of KRAS and its predictive value in CRC remain controversial. \u0000The study aimed to explore the effect of primary tumor localization on KRAS gene status in CRC. \u0000Methods: The study included 60 patients with colon and rectal cancer. The KRAS mutation test was performed on paraffin-coated tumor samples using PCR methods. Colon cancer was divided into right-sided colon cancer (RSCC) and left-sided colon cancer (LSCC). \u0000Results: KRAS mutation was found much more often in rectal cancer (RC) and sigmoid colon (SC) (p=0.413) than in tumors in other parts of the colon. A combined analysis of our data and previously published data showed that KRAS mutation was more common in PSTC, especially in the area of the hepatic bend of the colon than in LSTC (p=0.120). The association of the KRAS mutation with the patient’s age (p<0.012) and the duration of hospitalization (p<0.001) was established.> \u0000Conclusion: Our study revealed no significant difference in the KRAS status between colon cancer and rectal cancer. However, KRAS mutation was much more common in RSCC compared to LSCC. Patients with RSCC with mutated KRAS also had a worse prognosis and required longer hospitalization compared to wild-type KRAS. However, patients with LSCC did not demonstrate a similar effect.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140720138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CARCINOGENICITY OF IONIZING RADIATION: A LITERATURE REVIEW 电离辐射的致癌性:文献综述
Pub Date : 2023-12-29 DOI: 10.52532/2521-6414-2023-4-70-39-45
Y. Iztleuov, M. Iztleuov, A. Elubaeva, A. Tulyaeyva, N. Abenova
Relevance: According to WHO, malignant neoplasms rank second in population mortality structure due to a constantly increasing influence of technogenic factors that have a direct carcinogenic effect on the body and suppress defense mechanisms. Ionizing radiation plays a special role in the development of cancer. It is used in industry, agriculture, medicine, and scientific research as a diagnostic tool in modern healthcare and radiation therapy for cancer treatment. The consequences of radiation influence are not only the result of a direct effect on the body but also a delayed one through generations of parents and grandparents. According to the radiobiological hypothesis, any level of radiation, no matter how small, ОБЗОРЫ ЛИТЕРАТУРЫ Онкология и Радиология Казахстана, №4 (70) 2023 45 poses a risk of long-term consequences, including cancer, in exposed people and their descendants of the first two generations. That is, cancerous tumors are likely consequences of the influence of radiation. Despite various theories of the biological effect of low doses of ionizing radiation, most authors attach primary importance to DNA damage in the manifestation of genetic effects (the concept of non-threshold mutational action). The study aimed to highlight the role of ionizing radiation in tumorigenesis. Methods: Data from MEDLINE, Embase, Scopus, PubMed, Cochrane Central Register of Controlled Trials was analyzed to select and analyze relevant information over the past 10 years using the keywords: gamma irradiation, spontaneous oncogenesis, prevention of oncogenesis, Results: Radiation exposure may increase the risk of cancer development due to epigenetic changes leading to increased genomic instability (GI) and/or specific suppression of tumor suppressor genes. Changes in the TP53 gene network expression occur; the most significant genes as predictors of carcinogenesis are ST13, IER3, BRCAI, LRDD, and MRAS. Epigenetic changes also influence individual susceptibility to radiation-induced cancer. In addition to the mutagenic effects of ROS and AFN, there is also evidence that oxidative stress plays a fundamental role in epigenetic modifications. Conclusion: As a result of radiation exposure, damage occurs that causes genetic and epigenetic changes, leading to changes in the level of protein expression due to changes in the methylation of cytosine residues in DNA, modification of histones, and regulation of microRNA expression.
相关性:世卫组织称,恶性肿瘤在人口死亡率结构中位居第二,这是因为技术因素的影响不断增加,对人体产生直接致癌作用并抑制防御机制。电离辐射在癌症的发展中起着特殊作用。在工业、农业、医学和科学研究中,电离辐射被用作现代医疗的诊断工具和治疗癌症的放射疗法。辐射影响的后果不仅是对人体的直接影响,而且是通过父母和祖父母世代相传的延迟影响。根据放射生物学假说,任何程度的辐射,无论多么微小,都会对人体产生影响、№4 (70) 2023 45 有可能对接触者及其前两代的后代造成包括癌症在内的长期后果。也就是说,癌症肿瘤很可能是辐射影响的后果。尽管关于低剂量电离辐射生物效应的理论多种多样,但大多数作者都将 DNA 损伤作为遗传效应表现的首要因素(非阈值突变作用概念)。 本研究旨在强调电离辐射在肿瘤发生中的作用。 研究方法分析了来自 MEDLINE、Embase、Scopus、PubMed 和 Cochrane Central Register of Controlled Trials 的数据,以伽马辐照、自发肿瘤发生、预防肿瘤发生为关键词,筛选并分析了过去 10 年的相关信息:由于表观遗传学变化导致基因组不稳定性(GI)增加和/或肿瘤抑制基因的特异性抑制,辐照可能会增加癌症发生的风险。TP53 基因网络的表达发生了变化;预测癌症发生的最重要基因是 ST13、IER3、BRCAI、LRDD 和 MRAS。表观遗传变化也会影响个人对辐射诱发癌症的易感性。除了 ROS 和 AFN 的诱变作用外,还有证据表明氧化应激在表观遗传修饰中起着根本性的作用。 结论辐照造成的损伤会引起基因和表观遗传学的变化,导致 DNA 中胞嘧啶残基的甲基化、组蛋白的修饰和 microRNA 表达的调控引起蛋白质表达水平的变化。
{"title":"CARCINOGENICITY OF IONIZING RADIATION: A LITERATURE REVIEW","authors":"Y. Iztleuov, M. Iztleuov, A. Elubaeva, A. Tulyaeyva, N. Abenova","doi":"10.52532/2521-6414-2023-4-70-39-45","DOIUrl":"https://doi.org/10.52532/2521-6414-2023-4-70-39-45","url":null,"abstract":"Relevance: According to WHO, malignant neoplasms rank second in population mortality structure due to a constantly increasing influence of technogenic factors that have a direct carcinogenic effect on the body and suppress defense mechanisms. Ionizing radiation plays a special role in the development of cancer. It is used in industry, agriculture, medicine, and scientific research as a diagnostic tool in modern healthcare and radiation therapy for cancer treatment. The consequences of radiation influence are not only the result of a direct effect on the body but also a delayed one through generations of parents and grandparents. According to the radiobiological hypothesis, any level of radiation, no matter how small, ОБЗОРЫ ЛИТЕРАТУРЫ Онкология и Радиология Казахстана, №4 (70) 2023 45 poses a risk of long-term consequences, including cancer, in exposed people and their descendants of the first two generations. That is, cancerous tumors are likely consequences of the influence of radiation. Despite various theories of the biological effect of low doses of ionizing radiation, most authors attach primary importance to DNA damage in the manifestation of genetic effects (the concept of non-threshold mutational action). The study aimed to highlight the role of ionizing radiation in tumorigenesis. Methods: Data from MEDLINE, Embase, Scopus, PubMed, Cochrane Central Register of Controlled Trials was analyzed to select and analyze relevant information over the past 10 years using the keywords: gamma irradiation, spontaneous oncogenesis, prevention of oncogenesis, Results: Radiation exposure may increase the risk of cancer development due to epigenetic changes leading to increased genomic instability (GI) and/or specific suppression of tumor suppressor genes. Changes in the TP53 gene network expression occur; the most significant genes as predictors of carcinogenesis are ST13, IER3, BRCAI, LRDD, and MRAS. Epigenetic changes also influence individual susceptibility to radiation-induced cancer. In addition to the mutagenic effects of ROS and AFN, there is also evidence that oxidative stress plays a fundamental role in epigenetic modifications. Conclusion: As a result of radiation exposure, damage occurs that causes genetic and epigenetic changes, leading to changes in the level of protein expression due to changes in the methylation of cytosine residues in DNA, modification of histones, and regulation of microRNA expression.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139142722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MAJOR REASONS FOR HOSPITALIZATION TO ICU OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A LITERATURE REVIEW 急性淋巴细胞白血病患儿入住重症监护室的主要原因:文献综述
Pub Date : 2023-12-29 DOI: 10.52532/2521-6414-2023-4-70-46-50
Ye. Kurakbayev, B. Turdaliyeva, K. Umbetov, Ye. Sarsekbayev
Relevance: Acute lymphoblastic leukemia (ALL) is a common malignancy in children. Approximately 85% of ALLs have B-cell origin, and 15% are T-cell ALLs. Many patients diagnosed with hematologic cancer will require hospitalization in the intensive care unit (ICU) at some point in their treatment. The aim was to study the available literature on clinical deterioration in patients with АLL admitted to the ICU, the clinical significance and prognostic value of causes of clinical deterioration, and adverse outcomes in patients with АLL staying in the ICU. Methods: A descriptive cross-sectional study approach was used. We reviewed published sources from 2016 to 2023 to collect data on major reasons for ALL patients’ hospitalization to ICU. Results: First, the patient’s age at the time of initial diagnosis of ALL is crucial. Cure rates for B-cell ALL are higher between 1 and 9 years of age than in other age groups. Second, the initial white blood cell count during diagnosis is a prognostic indicator. Third, the specific subtype of ALL also affects prognosis. The risk factors emphasize the importance of comorbidities and infectious diseases, as well as monitoring and managing pulmonary and cardiovascular function in patients to avoid hospitalization in the ICU. The main causes of hospitalization in the ICU are complications related to chemotherapy, infection, and unplanned hospitalizations. Compared to normal-risk patients, high-risk patients had a higher rate of OIT hospitalization in the ICU. It is important to control chemotherapy and infections to reduce the number of admissions to the ICU in this group. Conclusion: Chemotherapy, concomitant and infectious diseases, hypoxia, and hemodynamic instability are reasons for hospitalization of these patients to ICU. The condition of various organs and systems shall be monitored.
相关性:急性淋巴细胞白血病(ALL)是儿童常见的恶性肿瘤。大约 85% 的急性淋巴细胞白血病起源于 B 细胞,15% 是 T 细胞急性淋巴细胞白血病。许多确诊为血液肿瘤的患者在治疗过程中都需要在重症监护室(ICU)住院治疗。 本文旨在研究有关入住重症监护室的АLLL患者临床病情恶化、临床病情恶化原因的临床意义和预后价值以及在重症监护室住院的АLLL患者不良预后的现有文献。 研究方法采用描述性横断面研究方法。我们查阅了2016年至2023年发表的资料,收集了ALL患者入住ICU的主要原因数据。 结果首先,初次诊断为ALL时患者的年龄至关重要。1至9岁的B细胞ALL治愈率高于其他年龄组。第二,诊断时的初始白细胞计数是预后指标。第三,ALL 的特定亚型也会影响预后。风险因素强调了合并症和感染性疾病的重要性,以及监测和管理患者的肺功能和心血管功能以避免在重症监护室住院的重要性。在重症监护室住院的主要原因是与化疗相关的并发症、感染和意外住院。与正常风险患者相比,高风险患者在重症监护室的 OIT 住院率更高。控制化疗和感染对减少这类患者入住重症监护室非常重要。 结论化疗、并发症和感染性疾病、缺氧和血流动力学不稳定是这些患者入住重症监护室的原因。应监测各器官和系统的状况。
{"title":"MAJOR REASONS FOR HOSPITALIZATION TO ICU OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A LITERATURE REVIEW","authors":"Ye. Kurakbayev, B. Turdaliyeva, K. Umbetov, Ye. Sarsekbayev","doi":"10.52532/2521-6414-2023-4-70-46-50","DOIUrl":"https://doi.org/10.52532/2521-6414-2023-4-70-46-50","url":null,"abstract":"Relevance: Acute lymphoblastic leukemia (ALL) is a common malignancy in children. Approximately 85% of ALLs have B-cell origin, and 15% are T-cell ALLs. Many patients diagnosed with hematologic cancer will require hospitalization in the intensive care unit (ICU) at some point in their treatment. The aim was to study the available literature on clinical deterioration in patients with АLL admitted to the ICU, the clinical significance and prognostic value of causes of clinical deterioration, and adverse outcomes in patients with АLL staying in the ICU. Methods: A descriptive cross-sectional study approach was used. We reviewed published sources from 2016 to 2023 to collect data on major reasons for ALL patients’ hospitalization to ICU. Results: First, the patient’s age at the time of initial diagnosis of ALL is crucial. Cure rates for B-cell ALL are higher between 1 and 9 years of age than in other age groups. Second, the initial white blood cell count during diagnosis is a prognostic indicator. Third, the specific subtype of ALL also affects prognosis. The risk factors emphasize the importance of comorbidities and infectious diseases, as well as monitoring and managing pulmonary and cardiovascular function in patients to avoid hospitalization in the ICU. The main causes of hospitalization in the ICU are complications related to chemotherapy, infection, and unplanned hospitalizations. Compared to normal-risk patients, high-risk patients had a higher rate of OIT hospitalization in the ICU. It is important to control chemotherapy and infections to reduce the number of admissions to the ICU in this group. Conclusion: Chemotherapy, concomitant and infectious diseases, hypoxia, and hemodynamic instability are reasons for hospitalization of these patients to ICU. The condition of various organs and systems shall be monitored.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139143057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TARGETED IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA: A CLINICAL CASE 肝细胞癌的靶向免疫疗法: 临床病例
Pub Date : 2023-12-29 DOI: 10.52532/2521-6414-2023-4-70-28-30
B. Kashakov, M. Akbarova
Relevance: Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. HCC is one of the most important problems of the oncology service of Kazakhstan, as it has a progressive course, late detection, low survival, and unfavorable prognosis. The study aimed to evaluate the use of targeted immunotherapy in treating hepatocellular carcinoma in a clinical example. Methods: The paper presents a clinical case of targeted immunotherapy in combination with Atezolizumab 1200 mg + Bevacizumab 800 mg, once every 3 weeks, in treating HCC in the Regional Oncology Center in Kyzylorda. Results: The first symptoms of liver damage appeared in 2018, at which time HCC was discovered. Viral hepatitis B was diagnosed in 2016. MRI OBP from 15.08.20: a picture of the right lobe of the liver in S5 – 9×7×6 cm, in S3 – 3.7 cm, in S7 – 3.0 cm, in S8 – 2.5 cm. During the follow-up examination (July 2021), the enzyme immunoassay revealed a high angiotensin-converting enzyme (ACE) level of 450.56 IU/ml; the abdominal CT scan showed no deterioration. Later, despite the therapy, ACE increased rapidly: 2,595.3 IU/ml (August 2021) and 2,142.25 IU/ml (September 2021), and the therapy was changed to Regorafenib. ACE continued to rise to 4,405 IU/ml (November 2021) and 18,005 IU/ml (December 2021). A control abdominal CT scan showed a moderate reduction in the size of the tumor. Taking into account a steady ACE increase, in February 2022, the patient was recommended therapy with Atezolizumab and Bevacizumab. In January 2023, the patient has already received 13 courses, and ACE continued to decrease: 1,932 IU/ml (January 2023), 53.38 IU/ml (February 2023), 16.07 IU/ml (March 2023), and the abdominal CT scan showed positive dynamics. Conclusion: Targeted immunotherapy showed its effectiveness in the described case of inoperable HCC and allowed the patient to continue living, working, and leading an active lifestyle for more than 18 months.
相关性:肝细胞癌(HCC)是最常见的肝脏恶性肿瘤。由于肝细胞癌具有进展性、发现晚、存活率低和预后不良等特点,因此是哈萨克斯坦肿瘤服务领域最重要的问题之一。 本研究旨在以临床实例评估靶向免疫疗法在治疗肝细胞癌中的应用。 方法:本文介绍了克孜勒奥尔达地区肿瘤中心采用靶向免疫疗法联合阿特珠单抗1200毫克+贝伐单抗800毫克治疗肝细胞癌的临床病例,每3周一次。 治疗结果2018年首次出现肝损伤症状,当时发现了HCC。病毒性乙型肝炎于 2016 年确诊。 20 年 8 月 15 日的 MRI OBP:肝脏右叶 S5 - 9×7×6 厘米,S3 - 3.7 厘米,S7 - 3.0 厘米,S8 - 2.5 厘米。随访检查(2021 年 7 月)期间,酶免疫测定显示血管紧张素转换酶(ACE)水平较高,为 450.56 IU/ml;腹部 CT 扫描显示病情没有恶化。后来,尽管进行了治疗,但 ACE 还是迅速升高:2,595.3 IU/ml(2021 年 8 月)和 2,142.25 IU/ml(2021 年 9 月),治疗改为瑞戈非尼。ACE 继续上升至 4,405 IU/ml(2021 年 11 月)和 18,005 IU/ml(2021 年 12 月)。对照组腹部 CT 扫描显示肿瘤大小适度缩小。 考虑到 ACE 的稳定增长,2022 年 2 月,医生建议患者使用 Atezolizumab 和 Bevacizumab 治疗。2023 年 1 月,患者已经接受了 13 个疗程的治疗,ACE 继续下降:1,932 IU/ml(2023 年 1 月)、53.38 IU/ml(2023 年 2 月)、16.07 IU/ml(2023 年 3 月),腹部 CT 扫描显示出积极的动态变化。 结论靶向免疫疗法在上述无法手术的 HCC 病例中显示出其有效性,并使患者在超过 18 个月的时间里能够继续生活、工作和积极的生活方式。
{"title":"TARGETED IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA: A CLINICAL CASE","authors":"B. Kashakov, M. Akbarova","doi":"10.52532/2521-6414-2023-4-70-28-30","DOIUrl":"https://doi.org/10.52532/2521-6414-2023-4-70-28-30","url":null,"abstract":"Relevance: Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. HCC is one of the most important problems of the oncology service of Kazakhstan, as it has a progressive course, late detection, low survival, and unfavorable prognosis. The study aimed to evaluate the use of targeted immunotherapy in treating hepatocellular carcinoma in a clinical example. Methods: The paper presents a clinical case of targeted immunotherapy in combination with Atezolizumab 1200 mg + Bevacizumab 800 mg, once every 3 weeks, in treating HCC in the Regional Oncology Center in Kyzylorda. Results: The first symptoms of liver damage appeared in 2018, at which time HCC was discovered. Viral hepatitis B was diagnosed in 2016. MRI OBP from 15.08.20: a picture of the right lobe of the liver in S5 – 9×7×6 cm, in S3 – 3.7 cm, in S7 – 3.0 cm, in S8 – 2.5 cm. During the follow-up examination (July 2021), the enzyme immunoassay revealed a high angiotensin-converting enzyme (ACE) level of 450.56 IU/ml; the abdominal CT scan showed no deterioration. Later, despite the therapy, ACE increased rapidly: 2,595.3 IU/ml (August 2021) and 2,142.25 IU/ml (September 2021), and the therapy was changed to Regorafenib. ACE continued to rise to 4,405 IU/ml (November 2021) and 18,005 IU/ml (December 2021). A control abdominal CT scan showed a moderate reduction in the size of the tumor. Taking into account a steady ACE increase, in February 2022, the patient was recommended therapy with Atezolizumab and Bevacizumab. In January 2023, the patient has already received 13 courses, and ACE continued to decrease: 1,932 IU/ml (January 2023), 53.38 IU/ml (February 2023), 16.07 IU/ml (March 2023), and the abdominal CT scan showed positive dynamics. Conclusion: Targeted immunotherapy showed its effectiveness in the described case of inoperable HCC and allowed the patient to continue living, working, and leading an active lifestyle for more than 18 months.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139147924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RECURRENCE OF OVARIAN CANCER: POSSIBLE CAUSES, EARLY DETECTION 卵巢癌复发:可能的原因、早期发现
Pub Date : 2023-12-29 DOI: 10.52532/2521-6414-2023-4-70-31-33
A. Zeineabedyn, S. Kulbayeva, G. Taiteli, A. Tin, E. Mekhteeva, Zh. Kudaikulova
Relevance: Early detection of ovarian cancer relapses and their treatment is among the most difficult in practical oncogynecology. Early diagnosis of ovarian cancer recurrence increases the effectiveness of treatment and gives a more favorable survival prognosis. The study aimed to show the possible cause of ovarian cancer recurrence and methods for early detection of relapses. Materials and methods: We systematically analyzed 31 cases of recurrent ovarian cancer treated at the Zhambyl Regional Center of Oncology and Surgery (Kazakhstan) in 2021-2022. We divided them by age, stage, period of relapse, type of histology, tumor grade, sites of recurrence, and symptoms of recurrence. Results: Ovarian cancer is most often detected in the late stages since, in the early stages, the disease is asymptomatic. Patients with advanced stages showed more relapses and distant metastases. Most ovarian cancer and this disease’s relapses are detected at 50-70 years old. The late stages give more distant and multiple relapses than the early stages and in terms of earlier. Moreover, according to histology results, mesenchymal tumors are more significant than epithelial and G3. Conclusion: The recurrence of ovarian cancer is an aggressively occurring disease. Based on the analysis work carried out, more than 70% of patients with recurrent ovarian cancer were aged 50-70 years, and the recurrence rate was higher at later stages (St III) or with a low-grade form of the tumor. All patients received platinum-based combination therapy. Targeted therapy (Bevacizumab) was administered in generalization of the process. More than 20% of all patients are resistant to platinum, whose relapse occurred before six months; the rest are sensitive to platinum with a later relapse. Based on everything, there is an increase in distant and multiple relapses in the late stages of ovarian cancer. This indicates the need to introduce screening programs based on cancer markers (CA-125) and diagnostic instrumental examinations (MRI/CT) to detect ovarian cancer in the early stages. After the treatment, all patients with this disease should be under active supervision, especially patients with low-grade tumors and in late stages.
相关性:卵巢癌复发的早期发现及其治疗是妇科肿瘤学中最困难的问题之一。 卵巢癌复发的早期诊断可提高治疗效果,并为患者提供更有利的生存预后。 本研究旨在说明卵巢癌复发的可能原因以及早期发现复发的方法。 材料和方法:我们系统分析了 2021-2022 年期间在占比勒地区肿瘤外科中心(哈萨克斯坦)接受治疗的 31 例复发性卵巢癌患者。我们按照年龄、分期、复发时间、组织学类型、肿瘤分级、复发部位和复发症状对这些病例进行了分类。 结果如下卵巢癌最常在晚期被发现,因为在早期,这种疾病是没有症状的。晚期患者复发和远处转移的情况较多。大多数卵巢癌和这种疾病的复发是在 50-70 岁发现的。晚期复发的远处转移和多发性转移比早期复发更多,复发时间也更早。此外,根据组织学结果,间质瘤比上皮瘤和 G3 肿瘤更重要。 结论卵巢癌复发是一种侵袭性疾病。根据已开展的分析工作,70%以上的复发性卵巢癌患者年龄在 50-70 岁之间,晚期(St III)或低级别肿瘤的复发率较高。所有患者都接受了铂类联合疗法。靶向治疗(贝伐单抗)在治疗过程中普遍使用。20%以上的患者对铂类药物产生耐药性,在六个月前复发;其余患者对铂类药物敏感,复发时间较晚。综上所述,卵巢癌晚期远处复发和多次复发的情况有所增加。这表明,有必要引入基于癌症标志物(CA-125)和诊断仪器检查(核磁共振成像/CT)的筛查计划,以便在早期阶段发现卵巢癌。治疗后,所有患者都应接受积极的监护,尤其是低级别肿瘤和晚期患者。
{"title":"RECURRENCE OF OVARIAN CANCER: POSSIBLE CAUSES, EARLY DETECTION","authors":"A. Zeineabedyn, S. Kulbayeva, G. Taiteli, A. Tin, E. Mekhteeva, Zh. Kudaikulova","doi":"10.52532/2521-6414-2023-4-70-31-33","DOIUrl":"https://doi.org/10.52532/2521-6414-2023-4-70-31-33","url":null,"abstract":"Relevance: Early detection of ovarian cancer relapses and their treatment is among the most difficult in practical oncogynecology. Early diagnosis of ovarian cancer recurrence increases the effectiveness of treatment and gives a more favorable survival prognosis. The study aimed to show the possible cause of ovarian cancer recurrence and methods for early detection of relapses. Materials and methods: We systematically analyzed 31 cases of recurrent ovarian cancer treated at the Zhambyl Regional Center of Oncology and Surgery (Kazakhstan) in 2021-2022. We divided them by age, stage, period of relapse, type of histology, tumor grade, sites of recurrence, and symptoms of recurrence. Results: Ovarian cancer is most often detected in the late stages since, in the early stages, the disease is asymptomatic. Patients with advanced stages showed more relapses and distant metastases. Most ovarian cancer and this disease’s relapses are detected at 50-70 years old. The late stages give more distant and multiple relapses than the early stages and in terms of earlier. Moreover, according to histology results, mesenchymal tumors are more significant than epithelial and G3. Conclusion: The recurrence of ovarian cancer is an aggressively occurring disease. Based on the analysis work carried out, more than 70% of patients with recurrent ovarian cancer were aged 50-70 years, and the recurrence rate was higher at later stages (St III) or with a low-grade form of the tumor. All patients received platinum-based combination therapy. Targeted therapy (Bevacizumab) was administered in generalization of the process. More than 20% of all patients are resistant to platinum, whose relapse occurred before six months; the rest are sensitive to platinum with a later relapse. Based on everything, there is an increase in distant and multiple relapses in the late stages of ovarian cancer. This indicates the need to introduce screening programs based on cancer markers (CA-125) and diagnostic instrumental examinations (MRI/CT) to detect ovarian cancer in the early stages. After the treatment, all patients with this disease should be under active supervision, especially patients with low-grade tumors and in late stages.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139144764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MODIFIABLE RISK FACTORS FOR COLORECTAL CANCER DEVELOPMENT: A LITERATURE REVIEW 大肠癌发病的可改变风险因素: 文献综述
Pub Date : 2023-12-29 DOI: 10.52532/2521-6414-2023-4-70-51-55
Z. Soltanova, S. Tokanova
Relevance: Colorectal cancer (CRC) is one of the most commonly diagnosed types of cancer worldwide. CRC incidence has increased in Kazakhstan, as in many other countries in the past decade. Therefore, it is important to identify risk factors contributing to this pathological process to develop primary prevention programs at regional and national levels. The study aimed to investigate modifiable risk factors for the development of colorectal cancer. Methods: A systematic search was conducted in electronic databases, including PubMed, Cochrane Library, eLibrary, CyberLeninka, and Google Scholar. The study included reports of randomized and cohort studies conducted on large populations, meta-analyses, systematic reviews, and original full-text articles in English and Russian, available in open access and containing statistically validated conclusions. Exclusion criteria encompassed brief reports, newspaper articles, and personal communications. The search depth covered ten years (2012-2022). Results: Published data reflect the significant influence on the development of colorectal cancer (CRC) of modifiable risk factors such as dietary habits, smoking, alcohol consumption, obesity, and physical inactivity. Conclusion: CRC is a polyetiological disease that arises under the influence of both internal and external factors. However, only 25-30% of CRC cases are associated with non-modifiable risk factors, such as genetic factors, personal history of polyps, and inflammatory bowel diseases. 70-75% of CRC cases occur sporadically and are linked to modifiable risk factors, including smoking, alcohol consumption, unhealthy diet, sedentary lifestyle, lack of physical activity, and obesity
相关性:结肠直肠癌(CRC)是全球最常诊断出的癌症类型之一。与其他许多国家一样,哈萨克斯坦的结直肠癌发病率在过去十年中也有所上升。因此,必须确定导致这一病理过程的风险因素,以便在地区和国家层面制定初级预防计划。 本研究旨在调查结直肠癌发病的可改变风险因素。 研究方法在电子数据库(包括 PubMed、Cochrane Library、eLibrary、CyberLeninka 和 Google Scholar)中进行了系统搜索。研究包括对大量人群进行的随机研究和队列研究报告、荟萃分析、系统综述,以及以开放获取方式提供并包含经统计学验证的结论的英文和俄文原创全文文章。排除标准包括简要报告、报纸文章和个人通讯。搜索深度覆盖十年(2012-2022 年)。 搜索结果已发表的数据表明,饮食习惯、吸烟、饮酒、肥胖和缺乏运动等可改变的风险因素对结直肠癌(CRC)的发病有重大影响。 结论结直肠癌是一种多病因疾病,受内部和外部因素的影响。然而,只有 25-30% 的 CRC 病例与不可改变的风险因素有关,如遗传因素、个人息肉病史和炎症性肠病。 70-75% 的 CRC 病例为偶发性,与可改变的风险因素有关,包括吸烟、饮酒、不健康饮食、久坐不动的生活方式、缺乏体育锻炼和肥胖。
{"title":"MODIFIABLE RISK FACTORS FOR COLORECTAL CANCER DEVELOPMENT: A LITERATURE REVIEW","authors":"Z. Soltanova, S. Tokanova","doi":"10.52532/2521-6414-2023-4-70-51-55","DOIUrl":"https://doi.org/10.52532/2521-6414-2023-4-70-51-55","url":null,"abstract":"Relevance: Colorectal cancer (CRC) is one of the most commonly diagnosed types of cancer worldwide. CRC incidence has increased in Kazakhstan, as in many other countries in the past decade. Therefore, it is important to identify risk factors contributing to this pathological process to develop primary prevention programs at regional and national levels. The study aimed to investigate modifiable risk factors for the development of colorectal cancer. Methods: A systematic search was conducted in electronic databases, including PubMed, Cochrane Library, eLibrary, CyberLeninka, and Google Scholar. The study included reports of randomized and cohort studies conducted on large populations, meta-analyses, systematic reviews, and original full-text articles in English and Russian, available in open access and containing statistically validated conclusions. Exclusion criteria encompassed brief reports, newspaper articles, and personal communications. The search depth covered ten years (2012-2022). Results: Published data reflect the significant influence on the development of colorectal cancer (CRC) of modifiable risk factors such as dietary habits, smoking, alcohol consumption, obesity, and physical inactivity. Conclusion: CRC is a polyetiological disease that arises under the influence of both internal and external factors. However, only 25-30% of CRC cases are associated with non-modifiable risk factors, such as genetic factors, personal history of polyps, and inflammatory bowel diseases. 70-75% of CRC cases occur sporadically and are linked to modifiable risk factors, including smoking, alcohol consumption, unhealthy diet, sedentary lifestyle, lack of physical activity, and obesity","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139142205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AZAT ILYASOVNA SHIBANOVA – A LIFE DEDICATED TO MEDICINE. TO THE 90TH JUBILEE 阿扎特-伊利亚索夫娜-希巴诺娃--献给医学的一生。献给 90 周年
Pub Date : 2023-12-29 DOI: 10.52532/2521-6414-2023-4-70-64-67
L. Belamanova, T. Turmukhanov
Azat Ilyasovna Shibanova – a veteran of Kazakhstan’s oncology service, the founder of the Clinical Cytology discipline in the Republic of Kazakhstan, Doctor of Medical Sciences, Professor, Honorary President of the Association of Clinical Cytologists of the Republic of Kazakhstan, Honorary Member of the International Academy of Cytology, the founder of the Association of Clinical Cytologists of the Republic of Kazakhstan. During her career, she trained a whole galaxy of cytologists and cytotechnicians currently working across Kazakhsta
阿扎特-伊利亚索夫娜-希巴诺娃(Azat Ilyasovna Shibanova)--哈萨克斯坦肿瘤学领域的资深专家,哈萨克斯坦共和国临床细胞学学科的创始人,医学博士,教授,哈萨克斯坦共和国临床细胞学协会名誉主席,国际细胞学学会名誉会员,哈萨克斯坦共和国临床细胞学协会创始人。 在她的职业生涯中,她培养了一大批细胞学家和细胞技术人员,他们目前在哈萨克斯坦各地工作。
{"title":"AZAT ILYASOVNA SHIBANOVA – A LIFE DEDICATED TO MEDICINE. TO THE 90TH JUBILEE","authors":"L. Belamanova, T. Turmukhanov","doi":"10.52532/2521-6414-2023-4-70-64-67","DOIUrl":"https://doi.org/10.52532/2521-6414-2023-4-70-64-67","url":null,"abstract":"Azat Ilyasovna Shibanova – a veteran of Kazakhstan’s oncology service, the founder of the Clinical Cytology discipline in the Republic of Kazakhstan, Doctor of Medical Sciences, Professor, Honorary President of the Association of Clinical Cytologists of the Republic of Kazakhstan, Honorary Member of the International Academy of Cytology, the founder of the Association of Clinical Cytologists of the Republic of Kazakhstan. During her career, she trained a whole galaxy of cytologists and cytotechnicians currently working across Kazakhsta","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139143743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
METHODS FOR IMPROVING THE DRG-05M DOSIMETER IN BRACHYTHERAPY 改进近距离放射治疗中的 drg-05m 剂量计的方法
Pub Date : 2023-12-29 DOI: 10.52532/2521-6414-2023-4-70-18-22
A. Tulegenova, D. Mussakhanov, K. Datbayev, M. Omirzak, O. Seitov
Relevance: The article discusses one of the ways to improve the DRG-05M dosimeter in brachytherapy by using new components and technologies in an improved scheme, which includes more accurate sensors, advanced signal processing techniques, efficient power cells, and other solutions. The application of such advanced components and technologies in the framework of DRG-05M dosimeter modernization is a new and original contribution to the field of dosimetry. The scientific novelty of the work is the improvement of the existing circuitry, namely, the improvement of the DRG-05M dosimeter’s electrical circuitry based on the analysis of its shortcomings. This includes replacing components, optimizing circuit structure, eliminating noise and interference, and improving the stability and accuracy of measurements. 1. дозиметрмен ФЭУ тұтынатын кернеу-1,5 кВ. біз 15 В ФЭУ ұсындық, бұл ағымдағы көрсеткіштен екі ретке төмен; 2. біз қазіргі дозиметрге қарағанда заманауи АЦТ микроконтроллерін пайдалануды ұсынамыз. Ұсынылған микроконтроллер өнімділігі жағынан жоғары, бұл өлшеу дәлдігіне тікелей әсер етеді; 3. біз бүкіл тізбектің қуат көзін максимум 15 в кернеуге ауыстыруды ұсынамыз. Дозиметрде бұрын қолданылған қуат блогы кернеуді 1,5 кВ-қа дейін арттырды және бірнеше вольтты шу шығарды. Жақсартылған схеманың сипаттамаларын дозиметрдің бастапқы нұсқасымен салыстыру брахитерапиядағы дозаны өлшеудің тиімділігін, сенімділігі мен дәлдігін көрсетеді. Пайдаланылған дереккөздердің тізімі: 1. Соколов А.К., Хайкович И.М., Дмитриев А.Н. Патент РФ 96124418/20, 25.12.1996. – Сцинтилляционный дозиметр. RU 6246 U1 МПК G01T 1/20 (1995.01) [Sokolov A.K., Khaikovich I.M., Dmitryev A.N. Patent. RF 96124418/20, 25.12.1996. – Scintillyatsyonnyi dozimetr RU 6246 U1 МПК G01T 1/20 (1995.01) (in Russ.)] https://www.fips.ru/cdfi/ fips.dll/ru?ty=29&docid=6246&ki=PM 2. Дозиметры ДРГ-05, ДРГ-05М / Паспорт ЖШ2.805.397 ПС. – 1987. [Dozimetry DRG-05, ДРГ-05М / Pasport ZhSh2.805.397 PS. – 1987. (in Russ.)]. 3. Федерков Б.Г., Телец В.А. Микросхемы ЦАП и АЦП: функционирование, параметры, применение. – М.: Энергоиздат, 1990. – 320 с. [Federkov B.G., Telets V.A. Microshemi TSAP i ATSP: funksionirovanie, parametri, primenenie. – M: Energoizdat, 1990. – 320 s. (in Russ.)]. http://scbist.com/knigi-i-zhurnaly/36127-b-g-fedorkov-vtelec-mikroshemy-cap-i-acp-1990-g.html 4. Texnic.ru. КР572ПВ5 схема [Texnic.ru. KR572PV5 sxema] . 19.12.2023. 5. Одинец А.И., Науменко А.П. Цифровые устройства: АЦП и ЦАП // Учеб. пособие. – Омск: Изд-во ИРСИД, 2006. – 48 с. [Odinec A.I., Naumenko A.P. Cifrovye ustrojstva: ACP i CAP // Ucheb. posobie. – Omsk: Izd-vo IRSID, 2006. – 48 s. (in Russ.)] https://rusneb.ru/ catalog/010003_000061_a3862e678cf0d42aab092b309ed1524a/ 6. Zloy Soft Company. №5872. Преобразователь постоянного напряжения 1.5В/15В [Zloy Soft Company. №5872. Preobrazovatel’ postoyannogo napryazheniya 1.5V/15V (in Russ.)]. http://cxema. my1.ru/publ/istochniki_pitanija/preobra
相关性: 文章讨论了通过在改进方案中使用新组件和技术来改进近距离放射治疗中的 DRG-05M 剂量计的方法之一,其中包括更精确的传感器、先进的信号处理技术、高效的动力电池和其他解决方案。在 DRG-05M 剂量计现代化框架内应用这些先进组件和技术,是对剂量测定领域的一项新的原创性贡献。这项工作的科学创新在于改进现有电路,即在分析 DRG-05M 剂量计缺点的基础上改进其电路。这包括更换元件、优化电路结构、消除噪声和干扰,以及提高测量的稳定性和准确性。 1.5 kV 核心。 1. 没有 15 V FEU,剂量计不配备 15 V FEU,但配备 15 V 微控制器;2.时,请勿将微控制器用于其他用途; 3. 内核电压最高不超过 15 伏时,请勿使用微控制器。kV 或更高电压的磁芯时,可使用剂量计。 或使用剂量计量装置来增加近距离放射治疗的剂量。 Paidalanylғan derekkөzdің tizimі: 1.Sokolov A.K., Khaykovich I.M., Dmitriev A.N. Patent RF 96124418/20, 25.12.1996.- 闪烁剂量计。RU 6246 U1 MPK G01T 1/20 (1995.01) [Sokolov A.K., Khaikovich I.M., Dmitriev A.N.专利号RF 96124418/20,25.12.1996。- Scintillyatsyonnyi dozimetr RU 6246 U1 MPK G01T 1/20 (1995.01) (in Russ.)] https://www.fips.ru/cdfi/ fips.dll/en?ty=29&docid=6246&ki=PM 2.Dosimeters DRG-05, DRG-05M / Passport ZhSh2.805.397 PS.- 1987.[DRG-05, DRG-05M / Passport ZhSh2.805.397 PS. - 1987. (in Russ.)]. 3.Federkov B.G., Telets V.A. DAC 和 ADC 微电路:功能、参数、应用。- 莫斯科:Energoizdat,1990 年。- 320 с.[Federkov B.G., Telets V.A. Microshemi TSAP i ATSP: funksionirovanie, parametri, primenenie.- M: Energoizdat, 1990.- 320 s.(in Russ.)]. http://scbist.com/knigi-i-zhurnaly/36127-b-g-fedorkov-vtelec-mikroshemy-cap-i-acp-1990-g.html 4.Texnic.ru.KR572PV5 sxema [Texnic.ru. KR572PV5 sxema] . 19.12.2023. 5.Odinets, A.I.; Naumenko, A.P. Digital devices: ADC and DAC (in Russian) // Tutorial.- Omsk: Izd-vo IRSID, 2006.- 48 с.[Cifrovye ustrojstva: ACP i CAP // Ucheb. posobie. - Omsk: Izd-vo IRSID, 2006.- 48 s.(in Russ.)] https://rusneb.ru/ catalogue/010003_000061_a3862e678cf0d42aab092b309ed1524a/ 6.Zloy Soft Company.№5872.1.5V/15V 恒压转换器 [Zloy Soft Company.№5872.Preobrazovatel' postoyannogo napryazheniya 1.5V/15V (in Russ.)]. http://cxema. my1.ru/publ/istochniki_pitanija/preobrazovateli_naprjazhenija/ preobrazovatel_postojannogo_naprjazhenija_1_5v_15v/101-1-0-5872 ORIGINAL RESEARCH 22 Oncology and Radiology of Kazakhstan, No. 4 (70) 2023 Zertteudің ashyktyғy:文章作者。 否则可能导致火灾或触电。 请注意:请勿将设备放置在哈萨克斯坦共和国卫生部、哈萨克斯坦共和国萨乌德和一体化部长 BR12967832 ZRN 的 "剂量测定和计量 "上。 作者:概念设计 - A.T. Tolegenova, D.A. Musakhanov;设计 - K.D. Datbaev, M.S. Emirzak、мғылыми zertteulerdі zүzege asyrу - A.T. Tөlegenova, M.S. Өmіrzak;мәлімделген ғылымиzertteulerdің解释 - Datbaev K.D. 、Seitov O.K.; ғылым мақұрылуың құрыluy-Төlegenova A.T., Мұсаханов D.A. 作者简介:Төlegenova Aida Төлегенқыzy (作者通信) - 哲学博士、"Әl-Farabi atyndagy KazҰU" KeA K,阿拉木图,哈萨克斯坦共和国,电话:+77079199951,电子邮件:tulegenova.aida@gmail.com;ORCID ID:0000-0002-5701-6674;Musakhanov Dosymkhan Әbitkhanuly - t.g.k、L.N. Gumilev atyndagdagh "无线电工程、电子和电信系。Gumilev atyndagy EҰU" KeA KU,哈萨克斯坦共和国阿斯塔纳,电话:+77019989787,电子邮件:Mussakhanov_da@enu.kz,ORCID ID:0000-0002-1823-2526; Datbaev Kaiyrgeldi Dauletuly - 硕士学位,工程师,剂量测定和剂量测定治疗,物理和工程,"KazORҒZI"。阿拉木图,哈萨克斯坦共和国,电话:+77718507486,电子邮件:kairdatbayev@gmail.
{"title":"METHODS FOR IMPROVING THE DRG-05M DOSIMETER IN BRACHYTHERAPY","authors":"A. Tulegenova, D. Mussakhanov, K. Datbayev, M. Omirzak, O. Seitov","doi":"10.52532/2521-6414-2023-4-70-18-22","DOIUrl":"https://doi.org/10.52532/2521-6414-2023-4-70-18-22","url":null,"abstract":"Relevance: The article discusses one of the ways to improve the DRG-05M dosimeter in brachytherapy by using new components and technologies in an improved scheme, which includes more accurate sensors, advanced signal processing techniques, efficient power cells, and other solutions. The application of such advanced components and technologies in the framework of DRG-05M dosimeter modernization is a new and original contribution to the field of dosimetry. The scientific novelty of the work is the improvement of the existing circuitry, namely, the improvement of the DRG-05M dosimeter’s electrical circuitry based on the analysis of its shortcomings. This includes replacing components, optimizing circuit structure, eliminating noise and interference, and improving the stability and accuracy of measurements. 1. дозиметрмен ФЭУ тұтынатын кернеу-1,5 кВ. біз 15 В ФЭУ ұсындық, бұл ағымдағы көрсеткіштен екі ретке төмен; 2. біз қазіргі дозиметрге қарағанда заманауи АЦТ микроконтроллерін пайдалануды ұсынамыз. Ұсынылған микроконтроллер өнімділігі жағынан жоғары, бұл өлшеу дәлдігіне тікелей әсер етеді; 3. біз бүкіл тізбектің қуат көзін максимум 15 в кернеуге ауыстыруды ұсынамыз. Дозиметрде бұрын қолданылған қуат блогы кернеуді 1,5 кВ-қа дейін арттырды және бірнеше вольтты шу шығарды. Жақсартылған схеманың сипаттамаларын дозиметрдің бастапқы нұсқасымен салыстыру брахитерапиядағы дозаны өлшеудің тиімділігін, сенімділігі мен дәлдігін көрсетеді. Пайдаланылған дереккөздердің тізімі: 1. Соколов А.К., Хайкович И.М., Дмитриев А.Н. Патент РФ 96124418/20, 25.12.1996. – Сцинтилляционный дозиметр. RU 6246 U1 МПК G01T 1/20 (1995.01) [Sokolov A.K., Khaikovich I.M., Dmitryev A.N. Patent. RF 96124418/20, 25.12.1996. – Scintillyatsyonnyi dozimetr RU 6246 U1 МПК G01T 1/20 (1995.01) (in Russ.)] https://www.fips.ru/cdfi/ fips.dll/ru?ty=29&docid=6246&ki=PM 2. Дозиметры ДРГ-05, ДРГ-05М / Паспорт ЖШ2.805.397 ПС. – 1987. [Dozimetry DRG-05, ДРГ-05М / Pasport ZhSh2.805.397 PS. – 1987. (in Russ.)]. 3. Федерков Б.Г., Телец В.А. Микросхемы ЦАП и АЦП: функционирование, параметры, применение. – М.: Энергоиздат, 1990. – 320 с. [Federkov B.G., Telets V.A. Microshemi TSAP i ATSP: funksionirovanie, parametri, primenenie. – M: Energoizdat, 1990. – 320 s. (in Russ.)]. http://scbist.com/knigi-i-zhurnaly/36127-b-g-fedorkov-vtelec-mikroshemy-cap-i-acp-1990-g.html 4. Texnic.ru. КР572ПВ5 схема [Texnic.ru. KR572PV5 sxema] . 19.12.2023. 5. Одинец А.И., Науменко А.П. Цифровые устройства: АЦП и ЦАП // Учеб. пособие. – Омск: Изд-во ИРСИД, 2006. – 48 с. [Odinec A.I., Naumenko A.P. Cifrovye ustrojstva: ACP i CAP // Ucheb. posobie. – Omsk: Izd-vo IRSID, 2006. – 48 s. (in Russ.)] https://rusneb.ru/ catalog/010003_000061_a3862e678cf0d42aab092b309ed1524a/ 6. Zloy Soft Company. №5872. Преобразователь постоянного напряжения 1.5В/15В [Zloy Soft Company. №5872. Preobrazovatel’ postoyannogo napryazheniya 1.5V/15V (in Russ.)]. http://cxema. my1.ru/publ/istochniki_pitanija/preobra","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139144713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PHOTODYNAMIC THERAPY FOR CERVICAL CANCER: A LITERATURE REVIEW 宫颈癌的光动力疗法:文献综述
Pub Date : 2023-12-29 DOI: 10.52532/2521-6414-2023-4-70-56-63
N. Shanazarov, G. Bariyeva, N. Mussin, R. Albayev, A. Kaliyev, E. Iztleuov, S. Smailova
Relevance: Cervical cancer is a major public health problem worldwide, with human papillomavirus infection playing a vital role as a risk factor. Photodynamic therapy is a minimally invasive treatment for HPV-related cervical lesions that uses photosensitizers and light to selectively destroy abnormal cells. The study aims to comprehensively review the different types of molecules used in PDT to reduce the morbidity and mortality associated with cervical cancer. Methods: A comprehensive search was conducted for all relevant articles investigating the efficacy and safety of PDT in the treatment of HPV-associated cervical cancer. PICO scores were determined for the review, and a literature search of the PubMed database was performed. An examination of the PubMed online database using keyword combinations identified 71 studies conducted between 2013 and 2023 that investigated using PDT to treat RSM cells. This article reviews ongoing clinical trials examining the efficacy of PDT in treating low-grade squamous cell intraepithelial neoplasia and high-grade squamous cell intraepithelial lesions, as well as preclinical approaches using different molecules for PDT in cervical cancer. Results: Potential molecules for PDT are described, their advantages and disadvantages evaluated, and solutions to improve their compatibility with antitumor treatment are proposed. Our review shows that PDT is a promising therapeutic approach for diagnosing and treating HPV-related cervical lesions. At the same time, we observe that using different classes of dyes enhances the anticancer effects of PDT. Conclusion: Fullerene and ALA-PDT are potential leaders for more intensive use in PDT, which will further help reduce the global incidence and mortality from cervical cancer. However, further studies are needed to evaluate its long-term efficacy and safety.
相关性:宫颈癌是全球主要的公共卫生问题,其中人类乳头瘤病毒感染是一个重要的风险因素。光动力疗法是一种治疗人乳头瘤病毒相关宫颈病变的微创疗法,它使用光敏剂和光来选择性地破坏异常细胞。 本研究旨在全面回顾光动力疗法中使用的不同类型分子,以降低与宫颈癌相关的发病率和死亡率。 研究方法对所有研究光动力疗法治疗 HPV 相关宫颈癌的有效性和安全性的相关文章进行了全面检索。为综述确定了 PICO 评分,并对 PubMed 数据库进行了文献检索。使用关键字组合对 PubMed 在线数据库进行了检查,发现在 2013 年至 2023 年期间进行的 71 项研究调查了使用 PDT 治疗 RSM 细胞的情况。 本文回顾了正在进行的临床试验,这些临床试验研究了PDT治疗低级别鳞状细胞上皮内瘤变和高级别鳞状细胞上皮内病变的疗效,以及使用不同分子进行PDT治疗宫颈癌的临床前方法。 结果:描述了潜在的光导疗法分子,评估了它们的优缺点,并提出了提高它们与抗肿瘤治疗兼容性的解决方案。我们的综述表明,PDT 是诊断和治疗 HPV 相关宫颈病变的一种很有前景的治疗方法。同时,我们还发现,使用不同种类的染料可以增强光导光疗的抗癌效果。 结论富勒烯和 ALA-PDT 有可能在光动力疗法中得到更广泛的应用,这将有助于进一步降低全球宫颈癌的发病率和死亡率。不过,还需要进一步的研究来评估其长期疗效和安全性。
{"title":"PHOTODYNAMIC THERAPY FOR CERVICAL CANCER: A LITERATURE REVIEW","authors":"N. Shanazarov, G. Bariyeva, N. Mussin, R. Albayev, A. Kaliyev, E. Iztleuov, S. Smailova","doi":"10.52532/2521-6414-2023-4-70-56-63","DOIUrl":"https://doi.org/10.52532/2521-6414-2023-4-70-56-63","url":null,"abstract":"Relevance: Cervical cancer is a major public health problem worldwide, with human papillomavirus infection playing a vital role as a risk factor. Photodynamic therapy is a minimally invasive treatment for HPV-related cervical lesions that uses photosensitizers and light to selectively destroy abnormal cells. The study aims to comprehensively review the different types of molecules used in PDT to reduce the morbidity and mortality associated with cervical cancer. Methods: A comprehensive search was conducted for all relevant articles investigating the efficacy and safety of PDT in the treatment of HPV-associated cervical cancer. PICO scores were determined for the review, and a literature search of the PubMed database was performed. An examination of the PubMed online database using keyword combinations identified 71 studies conducted between 2013 and 2023 that investigated using PDT to treat RSM cells. This article reviews ongoing clinical trials examining the efficacy of PDT in treating low-grade squamous cell intraepithelial neoplasia and high-grade squamous cell intraepithelial lesions, as well as preclinical approaches using different molecules for PDT in cervical cancer. Results: Potential molecules for PDT are described, their advantages and disadvantages evaluated, and solutions to improve their compatibility with antitumor treatment are proposed. Our review shows that PDT is a promising therapeutic approach for diagnosing and treating HPV-related cervical lesions. At the same time, we observe that using different classes of dyes enhances the anticancer effects of PDT. Conclusion: Fullerene and ALA-PDT are potential leaders for more intensive use in PDT, which will further help reduce the global incidence and mortality from cervical cancer. However, further studies are needed to evaluate its long-term efficacy and safety.","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139146481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Oncologia i radiologia Kazakhstana
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1